ArticleFrontiers in medicine2026
Three-year sublingual immunotherapy for HDM-induced allergic rhinoconjunctivitis: sustained ocular symptom improvement.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allergic conjunctivitis (AC) frequently coexists with allergic rhinitis (AR), together known as allergic rhinoconjunctivitis (ARC), but ocular symptoms are often underemphasized in efficacy assessments using composite scores. Therefore, this study aimed to isolate and quantify the therapeutic effect of house dust mite sublingual immunotherapy (HDM-SLIT) on ocular symptoms, providing targeted evidence for managing AC in HDM-sensitized patients. Methods: The complete clinical data of 150 patients with ARC aged 6-59 years who started HDM-SLIT for 3 years between March 2020 and May 2022 were retrospectively analyzed. The level of the total nasal symptom score (TNSS), total ocular symptom score (TOSS), total medication score (TMS), combined score of medication and rhinoconjunctivitis symptoms (CSMRS), the visual analog scale (VAS) score, and rhinoconjunctivitis quality of life questionnaire (RQLQ) were evaluated at baseline, 1, 2, and 3 years of treatment. Additionally, the occurrence of adverse events (AEs) was used to evaluate its safety. Results: Compared with baseline, significant improvements in TNSS, TOSS, TMS, CSMRS, and VAS scores were observed after 1, 2, and 3 years of SLIT (all Conclusion: Three-year HDM-SLIT yields significant, sustained, and progressive improvements in clinical outcomes and quality of life in patients with ARC, along with significant improvements in ocular symptoms and a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.